M. Nayrac

发表

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

D. Vézina, V. Martel-Laferrière, D. Kaufmann, 2022, Cell reports.

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

V. Martel-Laferrière, D. Kaufmann, C. Tremblay, 2021, bioRxiv.

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

V. Martel-Laferrière, D. Kaufmann, C. Tremblay, 2021, Cell Reports Medicine.

A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity

Justine C. Williams, E. Wherry, V. Martel-Laferrière, 2022, bioRxiv.

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

V. Martel-Laferrière, D. Kaufmann, C. Tremblay, 2022, bioRxiv.

Hepatitis E virus replication in human intestinal cells

J. Izopet, N. Kamar, P. Delobel, 2019, Gut.

Increase of CXCR3+ T cells impairs Th17 cells recruitment in the small intestine mucosa through IFN-γ and IL-18 during treated HIV-1 infection.

J. Izopet, C. Loiseau, P. Delobel, 2019, The Journal of infectious diseases.

Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals

J. Izopet, C. Loiseau, G. Martin-Blondel, 2020, Mucosal Immunology.

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection

D. Kaufmann, S. Anand, H. Medjahed, 2022, Viruses.

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

D. Vézina, V. Martel-Laferrière, D. Kaufmann, 2021, bioRxiv.

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells

Justine C. Williams, E. Wherry, V. Martel-Laferrière, 2022, iScience.

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

D. Vézina, V. Martel-Laferrière, D. Kaufmann, 2021, Cell Host and Microbe.

Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals

J. Izopet, C. Loiseau, G. Martin-Blondel, 2020, Mucosal Immunology.

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality

J. Richards, D. Kaufmann, A. Dyachenko, 2021, medRxiv.

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

D. Vézina, L. Stamatatos, V. Martel-Laferrière, 2021, Cell Host & Microbe.

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

D. Vézina, L. Stamatatos, V. Martel-Laferrière, 2021, bioRxiv.

Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction

D. Kaufmann, C. Tremblay, C. Chartrand-Lefebvre, 2021, Frontiers in Immunology.

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage

J. Richard, H. Medjahed, G. Gendron-Lepage, 2023, Viruses.

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

D. Vézina, V. Martel-Laferrière, D. Kaufmann, 2022, Cell reports.

A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery

R. Baric, Kelly D. Smith, S. Akilesh, 2022, Vaccines.